Vaccine therapies for pediatric malignancies

Cancer Journal

Volumn 11, Issue 4, 2005, Pages 331-339

  Rousseau, Raphaël F ^a   Brenner, Malcolm K ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Antigens; Immune suppression; Leukemia; Neuroblastoma; Vaccine therapy

Indexed keywords

BCG VACCINE; CANCER VACCINE; CD40 LIGAND; DENDRITIC CELL VACCINE; DNA VACCINE; ETOPOSIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 5; LYMPHOTACTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; PEPTIDE;

ACUTE LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; BONE PAIN; CANCER IMMUNOTHERAPY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG POTENTIATION; GENE TRANSLOCATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INJECTION PAIN; INJECTION SITE INFLAMMATION; LYMPHOCYTIC INFILTRATION; MYALGIA; NATURAL KILLER CELL; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; PANNICULITIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; ACUTE DISEASE; CHILD; DENDRITIC CELL; IMMUNOLOGY; LEUKEMIA;

ACUTE DISEASE; ANTIGENS, NEOPLASM; CANCER VACCINES; CHILD; DENDRITIC CELLS; HUMANS; LEUKEMIA; NEUROBLASTOMA; PEPTIDES;

EID: 33749575347     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200507000-00009     Document Type: Review

References (47)

1. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-839.
2. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
3. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369-396.
4. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21:713-758.
5. Owen-Schaub L et al. Fas and Fas ligand interactions in malignant disease. Int J Oncol 2000;17:5-12.
6. Trapani JA, Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003;15:533-543.
7. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900.
8. Wick M et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997;186:229-238.
9. Levey DL, Srivastava PK. Alterations in T cells of cancer-bearers: whence specificity? Immunol Today 1996;17:365-368.
10. Antony PA, Restifo NP. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 2002;25:202-206.
11. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-2478.
12. Reynolds JV et al. The influence of natural killer cells in neuroblastoma. Arch Surg 1989;124:235-239.
13. Handgretinger R et al. In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma. Pediatr Hematol Oncol 1989;6:307-317.
14. Foreman NK et al. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells: potential for residual disease eradication. Br J Cancer 1993;67:933-938.
15. Valteau D et al. T-cell receptor repertoire in neuroblastoma patients. Cancer Res 1996;56:362-369.
16. Caruso DA et al. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 2005;103:1280-1291.
17. Golumbek P, Lazenby A, Levitsky H. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-716.
18. Asher A, Mule J, Kasid A. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991;146:3227-3234.
19. Hock H et al. Interleukin 7 induces CD4+ T cell-dependant tumor rejection. J Exp Med 1991;174:1291-1298.
20. Watanabe Y, Kuribayashi K, Miyatake S. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989;86:9456-9460.
21. Main EK et al. Human neuroblastoma cell lines are susceptible to lysis by natural killer cells but not by cytotoxic T lymphocytes. J Immunol 1985;135:242-246.
22. Coze C et al. Characteristics and immunomodulatory properties of human neuroblastoma cells after retrovirus-mediated gene transfer of the cytokine genes IL-2 and IFN-gamma. Transgenics 1995;1:585-595.
23. Kennedy MK et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-780.
24. Croce M et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 2005;11[2 pt 1]:735-742.
25. Gimmi CD et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90:6586-6590.
26. Ranheim E, Kipps T. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependant signal. J Exp Med 1993;177:925-935.
27. Dilloo D et al. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997;90:1927-1933.
28. Dilloo D et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996;2:1090-1095.
29. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26:1335-1341.
30. Putzer BM et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 1997;94:10889-10894.
31. Chong H et al. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther 1998;5:223-232.
32. Emtage PC et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 1999;10:697-709.
33. Rousseau RF et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101:1718-1726.
34. Bowman L et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998;92:1941-1949.
35. Klingebiel T et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy: a pilot study. Eur J Cancer 1998;34:1398-1402.
36. Ratto GB et al. Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 2000;23:161-167.
37. Bowman LC et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998;9:1303-1311.
38. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
39. Faassen AE et al. CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur J Immunol 1995;25:3249-3255.
40. Yellin MJ et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153:666-674.
41. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378:617-620.
42. Schoenberger SP et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
43. Rousseau R et al. Treatment of high-risk acute leukemia with an autologous vaccine expressing transgenic IL-2 and CD40L. Blood 2002;11:867a.
44. De Angelo D et al. A phase I study of vaccination with lethally irradiated, autologous myeloblasts engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor. Blood 2001;98:1935a.
45. Borrello I et al. Posttransplant immunotherapy with a GM-CSF-based tumor vaccine (GVAX) following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML) [abstract]. Blood 2003;102:1791.
46. Qazilbash M et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. Blood 2004;104:259.
47. Oka Y et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-13890.